Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bendamustine
Drug ID BADD_D00230
Description Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Indications and Usage Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Marketing Status Prescription
ATC Code L01AA09
DrugBank ID DB06769
KEGG ID D07501
MeSH ID D000069461
PubChem ID 65628
TTD Drug ID D01CYA
NDC Product Code 68554-0050
Synonyms Bendamustine Hydrochloride | Hydrochloride, Bendamustine | Bendamustine | Bendamustin | Cytostasan | IMET 3393 | Ribomustin | Treanda | Zimet 3393
Chemical Information
Molecular Formula C16H21Cl2N3O2
CAS Registry Number 16506-27-7
SMILES CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Renal disorder20.01.02.0020.000533%Not Available
Renal failure20.01.03.0050.000417%Not Available
Respiratory distress22.02.01.0120.001332%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000486%
Respiratory tract irritation22.02.07.0120.000533%Not Available
Sepsis11.01.11.0030.001390%
Septic shock11.01.11.004; 24.06.02.0110.000417%Not Available
Sinus tachycardia02.03.03.0100.000533%
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.0070.001066%Not Available
Skin exfoliation23.03.07.0030.000533%Not Available
Skin lesion23.03.03.0100.001066%Not Available
Skin necrosis23.03.03.011--Not Available
Skin reaction23.03.03.013; 10.01.03.0190.000533%Not Available
Somnolence19.02.05.003; 17.02.04.006--
Squamous cell carcinoma16.16.01.0020.001598%Not Available
Squamous cell carcinoma of skin23.08.02.005; 16.03.02.0050.000799%Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.001332%
Stomatitis07.05.06.0050.001598%
Subdural haematoma24.07.04.005; 17.08.05.002; 12.01.10.0030.000278%Not Available
Swelling08.01.03.0150.001332%Not Available
Swelling face23.04.01.018; 10.01.05.0180.000799%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.008--
Tachycardia02.03.02.0070.001332%Not Available
Thrombocytopenia01.08.01.0020.003996%Not Available
Thrombosis24.01.01.006--Not Available
Tremor17.01.06.002--
Tumour lysis syndrome16.32.03.002; 14.05.01.0040.003730%
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000799%
Upper respiratory tract infection22.07.03.011; 11.01.13.0090.000533%
The 7th Page    First    Pre   7 8 9 10    Next   Last    Total 10 Pages